Eli Lilly and Company Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 112,476,000,000.00 | ROE | 23.59 % |
| Balance Sheet | Total Equity | 26,535,000,000.00 | ROA | 18.35 % |
| Cashflow | Capital Expenditures | -7,623,000,000.00 | P/FCF | 120.98 |
| Cashflow | Free Cash Flow | 8,972,000,256.00 | – | – |
| Cashflow | Operating Cash Flow | 16,813,000,000.00 | P/CF | 64.56 |
| Income | Earnings per Share (diluted) | 22.95 | Div. Yield | 0.50 % |
| Income | Net Income | 20,640,000,000.00 | P/E | 52.60 |
| Income | Shares Outstanding | 898,002,000.00 | P/B | 40.91 |
| Income | Total Revenue | 65,179,000,000.00 | P/S | 16.65 |
Ratios calculated on: 10/14/2026
Company Description
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company's products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company's new molecular entities (NMEs), which are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In February 2012, the Company acquired ChemGen Corp. On July 7, 2011, it acquired the animal health business of Janssen, a Johnson & Johnson company.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.lilly.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more